ACADIA Pharmaceuticals Inc - Asset Resilience Ratio
ACADIA Pharmaceuticals Inc (ACAD) has an Asset Resilience Ratio of 35.46% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of ACADIA Pharmaceuticals Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how ACADIA Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ACADIA Pharmaceuticals Inc (ACAD) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ACADIA Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of ACADIA Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $569.25 Million | 35.46% |
| Total Liquid Assets | $569.25 Million | 35.46% |
Asset Resilience Insights
- Very High Liquidity: ACADIA Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ACADIA Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare ACADIA Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ACADIA Pharmaceuticals Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for ACADIA Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.04% | $641.99 Million | $1.56 Billion | +4.30pp |
| 2024-12-31 | 36.74% | $436.40 Million | $1.19 Billion | +3.33pp |
| 2023-12-31 | 33.41% | $250.21 Million | $748.96 Million | -17.97pp |
| 2022-12-31 | 51.37% | $301.98 Million | $587.81 Million | -1.94pp |
| 2021-12-31 | 53.32% | $373.27 Million | $700.12 Million | +14.22pp |
| 2020-12-31 | 39.09% | $305.93 Million | $782.62 Million | -25.74pp |
| 2019-12-31 | 64.83% | $507.75 Million | $783.18 Million | +2.12pp |
| 2018-12-31 | 62.71% | $338.76 Million | $540.20 Million | -8.01pp |
| 2017-12-31 | 70.72% | $271.92 Million | $384.51 Million | +5.60pp |
| 2016-12-31 | 65.12% | $365.42 Million | $561.15 Million | +14.20pp |
| 2015-12-31 | 50.92% | $112.99 Million | $221.90 Million | -29.16pp |
| 2014-12-31 | 80.08% | $260.63 Million | $325.46 Million | -11.97pp |
| 2013-12-31 | 92.05% | $174.08 Million | $189.12 Million | +45.94pp |
| 2012-12-31 | 46.11% | $50.07 Million | $108.59 Million | -29.12pp |
| 2011-12-31 | 75.23% | $24.16 Million | $32.11 Million | -3.53pp |
| 2010-12-31 | 78.76% | $30.24 Million | $38.39 Million | +20.51pp |
| 2009-12-31 | 58.25% | $28.94 Million | $49.68 Million | -1.91pp |
| 2008-12-31 | 60.16% | $38.91 Million | $64.68 Million | -21.47pp |
| 2007-12-31 | 81.64% | $109.87 Million | $134.58 Million | +5.95pp |
| 2006-12-31 | 75.69% | $67.78 Million | $89.54 Million | +22.57pp |
| 2005-12-31 | 53.12% | $33.20 Million | $62.51 Million | -15.32pp |
| 2004-12-31 | 68.44% | $27.63 Million | $40.37 Million | +2.48pp |
| 2003-12-31 | 65.96% | $20.91 Million | $31.69 Million | +16.13pp |
| 2002-12-31 | 49.84% | $7.99 Million | $16.02 Million | -- |
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog … Read more